>
Fusion Pharmaceuticals Inc logo

FUSN - Fusion Pharmaceuticals Inc Share Price

$7.96 0.0  0.5%

Last Trade - 6:23pm

Sector
Healthcare
Size
Small Cap
Market Cap £244.6m
Enterprise Value £79.3m
Revenue £n/a
Position in Universe 4145th / 6998
Bullish
Bearish
Unlock FUSN Revenue
Momentum
Relative Strength (%)
1m -2.93%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -44.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 4.50
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, FusionPharmaceuticals Inc revenues was not reported. Net lossapplicable to common stockholders increased 51% to $17.5M.Higher net loss reflects Research and development -Balancing val increase from $4.3M to $10.1M (expense),General and administrative - Balancing v increase of 44% to$5.8M (expense), Stock-based Compensation in SGA increasefrom $285K to $1.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

FUSN Revenue Unlock FUSN Revenue

Net Income

FUSN Net Income Unlock FUSN Revenue

Normalised EPS

FUSN Normalised EPS Unlock FUSN Revenue

PE Ratio Range

FUSN PE Ratio Range Unlock FUSN Revenue

Dividend Yield Range

FUSN Dividend Yield Range Unlock FUSN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
FUSN EPS Forecasts Unlock FUSN Revenue
Profile Summary

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. Its technology enables it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. The Company’s lead product candidate is FPI-1434, that utilizes Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor I receptor (IGF-1R) with alpha emitting isotope actinium-225.

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated December 22, 2014
No. of Shareholders: 100
No. of Employees: 61
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 42,456,589
Free Float (0.0%)
Eligible for
ISAs
SIPPs
FUSN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for FUSN
Upcoming Events for FUSN
Monday 9th August, 2021 Estimate
Q2 2021 Fusion Pharmaceuticals Inc Earnings Release
Monday 8th November, 2021 Estimate
Q3 2021 Fusion Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Fusion Pharmaceuticals Inc
What is the Fusion Pharmaceuticals Inc share price?

As of 6:23pm, shares in Fusion Pharmaceuticals Inc are trading at $7.96, giving the company a market capitalisation of £244.6m. This share price information is delayed by 15 minutes.

How has the Fusion Pharmaceuticals Inc share price performed this year?

Shares in Fusion Pharmaceuticals Inc are currently trading at $7.96 and the price has moved by -47.79% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Fusion Pharmaceuticals Inc price has moved by -61.56% over the past year.

What are the analyst and broker recommendations for Fusion Pharmaceuticals Inc?

There are no analysts currently covering Fusion Pharmaceuticals Inc.

When will Fusion Pharmaceuticals Inc next release its financial results?

Fusion Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Fusion Pharmaceuticals Inc dividend yield?

Fusion Pharmaceuticals Inc does not currently pay a dividend.

Does Fusion Pharmaceuticals Inc pay a dividend?

Fusion Pharmaceuticals Inc does not currently pay a dividend.

When does Fusion Pharmaceuticals Inc next pay dividends?

Fusion Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Fusion Pharmaceuticals Inc shares?

To buy shares in Fusion Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Fusion Pharmaceuticals Inc?

Shares in Fusion Pharmaceuticals Inc are currently trading at $7.96, giving the company a market capitalisation of £244.6m.

Where are Fusion Pharmaceuticals Inc shares listed? Where are Fusion Pharmaceuticals Inc shares listed?

Here are the trading details for Fusion Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: FUSN
What kind of share is Fusion Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Fusion Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Fusion Pharmaceuticals Inc share price forecast 2021?

Shares in Fusion Pharmaceuticals Inc are currently priced at $7.96. At that level they are trading at 0.181% discount to the analyst consensus target price of 0.00.

Analysts covering Fusion Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.52 for the next financial year.

How can I tell whether the Fusion Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fusion Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -44.56%. At the current price of $7.96, shares in Fusion Pharmaceuticals Inc are trading at -26.03% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Fusion Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Fusion Pharmaceuticals Inc.

Who are the key directors of Fusion Pharmaceuticals Inc?

Fusion Pharmaceuticals Inc's management team is headed by:

John Valliant - CEO
Eric Burak - CSO
Johan Christenson - DRC
Maria Stahl - OTH
Barbara Duncan - DRC
John Crowley - CFO
Philina Lee - DRC
Donald Bergstrom - DRC
Who are the major shareholders of Fusion Pharmaceuticals Inc?

Here are the top five shareholders of Fusion Pharmaceuticals Inc based on the size of their shareholding:

HealthCap AB Venture Capital
Percentage owned: 8.97% (3.81m shares)
Johnson & Johnson Innovation-JJDC, Inc. Venture Capital
Percentage owned: 8.65% (3.67m shares)
Varian Medical Systems, Inc. Corporation
Percentage owned: 7.67% (3.26m shares)
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 7.6% (3.22m shares)
Canada Pension Plan Investment Board Pension Fund Portfolio
Percentage owned: 7.34% (3.12m shares)
Similar to FUSN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.